Yang Yuan-Min, Chen Li-Na, Qu Shui-Qing, Deng Shuo-Qiu, Liu Hui, Wang Xi, Weng Xiao-Gang, Wang Ya-Jie, Zhu Xiao-Xin, Li Yu-Jie
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China Artemisinin Research Center, China Academy of Chinese Medical Sciences Beijing 100700, China.
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China School of Traditional Chinese Medicine, Guangdong Pharmaceutical University Guangzhou 510006, China.
Zhongguo Zhong Yao Za Zhi. 2020 Dec;45(24):6053-6064. doi: 10.19540/j.cnki.cjcmm.20200828.601.
Corona virus disease 2019(COVID-19) has brought untold human sufferings and economic tragedy worldwide. It causes acute myocardial injury and chronic damage of cardiovascular system, which has attracted much attention from researchers. For the immediate strategy for COVID-19, "drug repurposing" is a new opportunity for developing drugs to fight COVID-19. Artemisinin and its derivatives have a wide range of pharmacological activities. Recent studies have shown that artemisinin has clear cardiovascular protective effects. This paper summarizes the research progress on the pathogenesis the pathogenesis of COVID-19 in cardiovascular damage by 2019 novel coronavirus(2019-nCoV) virus from myocardial cell injury directly by 2019-nCoV virus,viral ligands competitively bind to ACE2 and then reduce the protective effect of ACE2 on cardiovascular disease, "cytokine storm" related myocardial damage, arrhythmia and sudden cardiac death induced by the infection and stress, myocardial injury by hypoxemia, heart damage side effects from COVID-19 drugs and summarizing the cardiovascular protective effects of artemisinin and its derivatives have activities of anti-arrhythmia, anti-myocardial ischemia, anti-atherosclerosis and plaque stabilization. Then analyzed the possible multi-pathway intervention effects of artemisinin-based drugs on multiple complications of COVID-19 based on its specific immunomodulatory effects, protective effects of tissue and organ damage and broad-spectrum antiviral effect, to provide clues for the treatment of cardiovascular complications of COVID-19, and give a new basis for the therapy of COVID-19 through "drug repurposing".
2019年冠状病毒病（COVID-19）在全球范围内带来了巨大的人类苦难和经济悲剧。它会导致急性心肌损伤和心血管系统的慢性损害，这引起了研究人员的广泛关注。对于COVID-19的即时策略，“药物重新利用”是开发抗击COVID-19药物的新机遇。青蒿素及其衍生物具有广泛的药理活性。最近的研究表明，青蒿素具有明确的心血管保护作用。本文总结了关于2019新型冠状病毒（2019-nCoV）导致COVID-19心血管损伤发病机制的研究进展，包括2019-nCoV病毒直接导致心肌细胞损伤、病毒配体竞争性结合血管紧张素转换酶2（ACE2）进而降低ACE2对心血管疾病的保护作用、“细胞因子风暴”相关的心肌损伤、感染和应激诱导的心律失常和心源性猝死、低氧血症导致的心肌损伤、COVID-19药物的心脏损害副作用，并总结了青蒿素及其衍生物的心血管保护作用，其具有抗心律失常、抗心肌缺血、抗动脉粥样硬化和斑块稳定的活性。然后基于青蒿素类药物特定的免疫调节作用、组织和器官损伤保护作用以及广谱抗病毒作用，分析了其对COVID-19多种并发症可能的多途径干预作用，为治疗COVID-19心血管并发症提供线索，并为通过“药物重新利用”治疗COVID-19提供新的依据。
